Betalutin
Nordic Nanovector
['lymphoma', 'dlbcl', 'nordic']
nordic nanovector announces that the data from the lymrit 37-05 phase 1 trial of betalutin in relapsed/refractory diffuse large b-cell lymphoma (dlbcl) will be presented at eha 2022 meeting 
Press- and earnings-releases in English and Swedish.